AFM
TNXP icon

Anson Funds Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Anson Funds Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed -$309K – 429
2021
Q4 		$309K Buy
+1
New +$318K 0.03% 274
2019
Q1 		– Hold
0
– -$68K – 48
2018
Q4 		– Hold
0
– – – 49

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Anson Funds Management's TNXP Position: Q1 2022 in Review

Anson Funds Management sold out of Tonix Pharmaceuticals (TNXP) in Q1 2022, closing a stake of 1 share — an estimated $309K sold.

Anson Funds Management first reported a position in TNXP in Q4 2021 and held it in 1 quarter. The position peaked at $309K in Q4 2021. 18 funds tracked by Wall St. Rank hold TNXP as of Q1 2022.

  • Anson Funds Management reported no remaining Tonix Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 1 Tonix Pharmaceuticals share in Q1 2022, an estimated $309K.
  • Anson Funds Management first reported a position in Tonix Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Tonix Pharmaceuticals position peaked at $309K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.